Spyre Therapeutics Reports Positive Phase 2 Data for SPY002 in Ulcerative Colitis, Meeting Primary Endpoint
SYRE has more than doubled off its 52-week low of $13.93.
Summary
Spyre Therapeutics reported positive 12-week induction data from its Phase 2 SKYLINE trial for SPY002 in ulcerative colitis, meeting the primary endpoint and demonstrating strong efficacy and a favorable safety profile.
Key Events · Product Development and Regulatory · SYRE
-
SPY002 Achieves Primary Endpoint
SPY002 met its primary endpoint in the Phase 2 SKYLINE trial for ulcerative colitis, demonstrating a statistically significant 10.7-point reduction in Robarts Histopathology Index (RHI) score (p<0.0001) at Week 12.
-
Strong Secondary Efficacy Outcomes
The trial reported robust rates of clinical remission (33%) and endoscopic improvement (42%), along with a meaningful change in modified Mayo Score (-3.7), which are noted as being among the highest reported in UC.
-
Favorable Safety Profile
SPY002 was well tolerated with a safety profile consistent with the TL1A class. Two serious adverse events were reported but deemed not drug-related.
-
Pipeline Advancement and Future Readouts
These results build upon impressive SPY001 data and reinforce the company's strategy for optimized monotherapy components. Spyre remains on track to report Part A data for SPY003 (anti-IL-23) in Q3 2026 and is enrolling Part B of the SKYLINE trial for combination arms.
Analysis · SYRE · Life Sciences
Spyre Therapeutics announced highly positive Phase 2 SKYLINE trial data for SPY002 in ulcerative colitis, achieving its primary endpoint with a statistically significant reduction in the RHI score. The results, described as 'among the highest reported in UC' and 'potential best-in-class,' significantly de-risk the program and bolster the company's pipeline, especially following previous positive data for SPY001. This strong clinical validation could accelerate SPY002's development and enhance its market potential.
At the time of this filing, SYRE was trading at $82.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7B. The 52-week trading range was $13.93 to $84.43. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.